• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Sage Therapeutics

Quote
Well I thought the hiring and start date were well ahead..the Padufa date is mid Dec so not in field till Jan or after training..it would be hard to keep working my job for so long before the start date. No one wants to burn bridges..I will call my recruiter Gary tomm. Anyone else heard the hiring events were set further out?
 












anonymous said:
Yes, it's has been pushed back to the two last weeks of Sept. No word on why the delay.
Click to expand...

It was delayed because the FDA is concerned about delivery method since they say it has to be done exactly as it was done in the studies or this is a "no go."

Sage wants to have multiple methods which would be off-label promotion since in the studies they had to be monitored and couldn't do "at home infusion pumps."

This is not good!
 








anonymous said:
It was delayed because the FDA is concerned about delivery method since they say it has to be done exactly as it was done in the studies or this is a "no go."

Sage wants to have multiple methods which would be off-label promotion since in the studies they had to be monitored and couldn't do "at home infusion pumps."

This is not good!
Click to expand...
I posted long ago...60 hour in-patient hospital infusion and I was poo pood. Told I was stupid. You realize study design dictates FDA label. I can not believe how stupid Pharma reps are
 












anonymous said:
It was delayed because the FDA is concerned about delivery method since they say it has to be done exactly as it was done in the studies or this is a "no go."

Sage wants to have multiple methods which would be off-label promotion since in the studies they had to be monitored and couldn't do "at home infusion pumps."

This is not good!
Click to expand...
 




anonymous said:
It was delayed because the FDA is concerned about delivery method since they say it has to be done exactly as it was done in the studies or this is a "no go."

Sage wants to have multiple methods which would be off-label promotion since in the studies they had to be monitored and couldn't do "at home infusion pumps."

This is not good!
Click to expand...
You sound like you are privy to corporate intel. Probably best to go hide under your desk at this point.
 




You must have been offered a job as a Key Account Manager? Based on the current label your job would be critical to the company successfully launching brexanolone and generating income. The company has another product with breakthrough designation status from the FDA.

The delay will force them to look ahead to the strategy for their secondary product and deploy their inaugural sales team to launch brexanolone and prepare the market/build rapport to maximize secondary launch as well.

You better believe Sage’s strategy consultants are working overtime as well as those negotiating with the FDA. This deflates the balloon a little, but Sage has lots of long term upside potential IMO.

#ThisIsStartUpLife #ThisIsSage

anonymous said:
Dang I was getting pumped to get started because I have an offer in hand but now I’m nervous. Anyone else nervous that it got pushed back or should I be okay
Click to expand...
 




anonymous said:
You will soon find out it is that way! A lot of retreads from Novo and Amgen! If you weren’t in their club then, you won’t be in their club now!
Click to expand...
agreed. If you know people in the industry by experience ect..., you will find that a number of the RBD and AD's are from the scrap heap of Big Pharma previous job fails. Nothing new here. Will still be micromanagement, calls per day, live in the target HVP guest house kind of mentality. Do some research on the RBD and AD' s ... you'll see what I'm talking about.
 












anonymous said:
You must have been offered a job as a Key Account Manager? Based on the current label your job would be critical to the company successfully launching brexanolone and generating income. The company has another product with breakthrough designation status from the FDA.

The delay will force them to look ahead to the strategy for their secondary product and deploy their inaugural sales team to launch brexanolone and prepare the market/build rapport to maximize secondary launch as well.

You better believe Sage’s strategy consultants are working overtime as well as those negotiating with the FDA. This deflates the balloon a little, but Sage has lots of long term upside potential IMO.

#ThisIsStartUpLife #ThisIsSage
Click to expand...
Upcoming AdComm mtg in NOV. will most likely be focused on where drug is administered based on clinical trials. Lots of banter around IF it is safe for in-home infusion. Sage can’t answer that question.
 




After / when the drug is approved, the DEA still has 90 days to classify it. All of Q1 2019, will be about PPD education and booking luncheons for April. No selling until the DEA classifies the drug. Maybe by that time, Sage will have figured out the comp plan.
 




anonymous said:
After / when the drug is approved, the DEA still has 90 days to classify it. All of Q1 2019, will be about PPD education and booking luncheons for April. No selling until the DEA classifies the drug. Maybe by that time, Sage will have figured out the comp plan.
Click to expand...
Sage is starting to look like a company to monitor early on and if things go well, jump in during an expansion. But that is unless you need something sooner. The odds on success early on are decreasing but still may turn out great.....
 
















Top Bottom
Back
Quote